Skip to content
10-Q

Quarterly Report

Urovant Sciences Ltd.

0001564590-20-040068

← back to feed
Filed
Aug 13, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · Aug 12, 2020 31.18M sh
Operating Cash Flow Q1 2020 · Jun 30, 2020 −$30.8M
Operating Cash Flow Q1 2020 · Jun 30, 2019 −$22.51M
Long Term Debt Q1 2020 · Jun 30, 2020 $128.27M
Cash And Equivalents Q1 2020 · Jun 30, 2020 $63.04M
Cash And Equivalents Q1 2020 · Mar 31, 2020 $51.41M
Stockholders Equity Q1 2020 · Jun 30, 2020 −$84.94M
Stockholders Equity Q1 2020 · Mar 31, 2020 −$58.01M
Stockholders Equity Q1 2020 · Jun 30, 2019 $47.72M
Stockholders Equity Q1 2020 · Mar 31, 2019 $74.77M
Current Liabilities Q1 2020 · Jun 30, 2020 $30.57M
Current Liabilities Q1 2020 · Mar 31, 2020 $30.93M
Total Liabilities Q1 2020 · Jun 30, 2020 $163.07M
Total Liabilities Q1 2020 · Mar 31, 2020 $121.3M
Current Assets Q1 2020 · Jun 30, 2020 $72.27M
Current Assets Q1 2020 · Mar 31, 2020 $58.32M
Total Assets Q1 2020 · Jun 30, 2020 $78.14M
Total Assets Q1 2020 · Mar 31, 2020 $63.3M
Sga Expense Q1 2020 · Jun 30, 2020 $12.49M
Sga Expense Q1 2020 · Jun 30, 2019 $5.47M
Rd Expense Q1 2020 · Jun 30, 2020 $16.35M
Rd Expense Q1 2020 · Jun 30, 2019 $22.01M
Net Income Q1 2020 · Jun 30, 2020 −$30.49M
Net Income Q1 2020 · Jun 30, 2019 −$28.49M